| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 402.48 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Background and aims: Several experimental and clinical
studies have suggested that microRNAs (miRNAs) could be
potential epilepsy biomarkers. Nowadays, research has
been focused in miR-134, a brain-specific miRNA that
plays important roles in dendritic spine development and
neuronal structure regulation. An upregulation of miR-134
has been reported both in brain tissue of experimental
models (Jimenez-Mateos 2012) and plasma from epileptic
patients (Sun 2017). It has also been observed that some
anti-seizure drugs down regulate mir-134 plasmatic levels
(Sun 2017) highlighting the role of this miRNA in
epileptogenesis. Our aim was to quantify miR-134 serum
levels in a cohort of Mesial Temporal Lobe Epilepsy
(MTLE) patients and correlate with clinical characteristics
such as drug response.
Description
Keywords
Epilepsy Doenças Genéticas
